When.com Web Search

  1. Ads

    related to: reach 3 ruxolitinib 20 mg cap risi 10

Search results

  1. Results From The WOW.Com Content Network
  2. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

  3. Deuruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Deuruxolitinib

    Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. [1] It is a Janus kinase inhibitor selective for JAK1 and JAK2. [2]

  4. New Data for Jakafi® (ruxolitinib) Presented at the 2012 ...

    www.aol.com/news/2012-12-10-new-data-for-jakafi...

    Harrison, C, et al. EXPAND: a Phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 × 10 9 /L and 99 × 10 9 /L. 2012 ASH ...

  5. Rociletinib - Wikipedia

    en.wikipedia.org/wiki/Rociletinib

    Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. [1]

  6. Baricitinib - Wikipedia

    en.wikipedia.org/wiki/Baricitinib

    Then in May 2022, the FDA approved use of baricitinib for the treatment of adults hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever happens first.

  7. Pelabresib - Wikipedia

    en.wikipedia.org/wiki/Pelabresib

    A phase one study of pelabresib in patients with relapsed/refractory lymphomas found pelabresib is capable of BET target gene suppression in an exposure-dependent manner with an acceptable safety profile leading to the recommended phase II dose of the 125 mg tablet once daily. [3] [4]

  1. Ads

    related to: reach 3 ruxolitinib 20 mg cap risi 10